The rollout of life-saving malaria vaccines is accelerating in Ghana, Kenya & Malawi

Last week, Cameroon became the first African country to receive the Mosquirix malaria vaccine for use as a fully tested preventative in a wide range of health facilities. A shipment containing more than 331,000 doses arrived yesterday at the airport in the capital, Yaoundé. The vaccine was successfully tested on children in Ghana, Kenya and Malawi for four years.

Malaria is a mosquito-borne disease that carries a particularly high burden of disease among children in Africa. In the 20th century alone, malaria caused between 150 and 300 million deaths worldwide. Every year, almost 600,000 children die from the communicable disease worldwide, more than 500,000 of them in Africa. The vast majority of victims are under five years old.


Don't miss any Jobs + Tips on Samuel Kwame Boadu's Telegram. Click on Subscribe Now !

Until the late 1990s, malaria was considered one of the world’s neglected tropical diseases. At that time, the World Health Organization described the “big three” infectious diseases HIV, tuberculosis and malaria as the deadliest “poverty-related” diseases in developing countries.

This led to the creation of the Global Fund to Fight AIDS, Tuberculosis and Malaria, which mobilized significant resources to advance the prevention and treatment of all three diseases. The work of the Global Fund and the provision of research and development funding for malaria has borne fruit.


Don't miss any Jobs + Tips on Samuel Kwame Boadu's Telegram. Click on Subscribe Now !

Mosquirix, RTS, S/AS01, is a recombinant protein-based vaccine. The vaccine was originally developed in 1987, but it took more than 30 years until a pilot program began in 2019 for implementation in endemic countries.

This first-generation malaria vaccine shows moderate effectiveness against the disease and promises to be an important public health tool, particularly for children in areas with high transmission and high mortality.

The rollout of life-saving malaria vaccines is accelerating in Ghana, Kenya & Malawi
February 13, 2019 in Ndhiwa, Homabaya County, western Kenya during the test launch of a malaria vaccine in Kenya. The vaccine – Mosquirix – is the world’s first malaria vaccine proven to provide partial protection against malaria in young children and has been introduced by the World Health Organization in Kenya, Ghana and Malawi. (Photo by Brian ONGORO/AFP) (Photo by BRIAN ONGORO/AFP via Getty Images) AFP via Getty Images


WHO granted prequalification to Mosquirix in 2021, meaning United Nations agencies such as UNICEF could procure the vaccine in partnership with Gavi, the Vaccine Alliance and eligible countries.


Don't miss any Jobs + Tips on Samuel Kwame Boadu's Telegram. Click on Subscribe Now !

By 2022, the vaccine had been administered to approximately one million children living in areas with moderate to high malaria transmission as part of an extensive testing program.

But now Cameroon is the first African country to begin using Mosquirix as a fully tested preventative in numerous health facilities across the country. This first shipment of vaccines will be distributed to 42 of the country’s 203 health districts. And the first vaccinations are expected to be administered within a month and will mainly be given to children under five.

The Mosquirix vaccine will be rolled out further next year in nine countries where malaria is endemic. In addition, around 18 African countries are expected to receive 18 million doses over the next two years. By 2026, demand across Africa could reach 40 to 60 million doses.

Vaccines like Mosquirix save children’s lives. In the areas where Mosquirix was tested, child mortality fell by 13%. Clinical researchers and healthcare workers believe this will save tens of thousands of children’s lives.

The WHO has now also recommended a second malaria vaccination. This vaccine, R21/Matrix-M, is cheaper and will be available by the middle of next year.

The start of mass administration of an approved malaria vaccine represents an important global public health effort that will help reduce the burden of disease and save lives.

I am an independent healthcare analyst with more than 24 years of experience in healthcare and pharmaceutical analysis. Specifically, I analyze the value (costs and benefits) of biologics and pharmaceuticals, patient access to prescription drugs, the regulatory framework for drug development and reimbursement, and the ethics surrounding the distribution of healthcare resources. I have approximately 110 publications in peer-reviewed journals and hundreds of articles in newspapers and magazines. Additionally, I have presented my work at numerous commercial, industry and academic conferences. From 1999 to 2017, I was a research fellow at the Tufts Center for the Study of Drug Development. Prior to my appointment at Tufts, I was a postdoctoral fellow at the University of Pennsylvania and received my Ph.D. in Economics from the University of Amsterdam. Before my doctorate, I was a management consultant at Accenture in The Hague, Netherlands. I am currently working freelance on a variety of research, teaching and writing projects for the past 6 years.

Source: Samuel Kwame Boadu’s Journal

Free In Inbox

Start your day with our news digest for entrepreneurs.